Quantitative EEG Correlates of Suicidal Behaviors in Children and Adolescents


About this study

The purpose of this study is to examine qEEG correlates of suicidal ideations and behaviors (SIBS) (screened by the Columbia-Suicide Severity Rating Scale (C-SSRS)) in hospitalized adolescents between the ages of 13-18 years as compared to age-matched healthy participants.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

For all participants

  • Ages 13-18;
  • Any gender, race or ethnicity;
  • Able to provide informed assent, and legal guardians able to provide informed consent if under 18 .

For patients

  • Being admitted to Generose 1-West with active suicidal ideations, suicidal behaviours (significant planning/preparation, attempt or aborted attempt) or non-suicidal self-injury.

Exclusion Criteria:

For all participants

  • Active co-morbid substance use meeting diagnostic criteria in MINI or MINI-KID (within the last month with the exception of caffeine and tobacco);
  • Neurological disorders including seizure disorder, anoxia history, history of head injuries with loss of consciousness for greater than 5 minutes;
  • Unable to read, speak or write English;
  • Refusal or withdrawal of consent, inability or unwillingness to adhere to study procedures.
  • Any non-removable hair extensions and or hair styling that would impede proper EEG recording;
  • Pregnancy or suspected pregnancy in female participants (assessed with urine pregnancy test).

For patients

  • Active psychosis or mania;
  • Autism spectrum disorder;
  • Intellectual disability;
  • Schizophrenic spectrum illness;
  • Antiepileptic medication use (valproic acid, carbamazepine, oxacarbamazapine, lamotrigine, gabapentin or topiramate), chronic benzodiazepine use or stimulant use (as needed benzodiazepine or stimulant use will be permitted if it can be held for at least 24 hour prior to the study visit);
  • Suicide attempt by significant overdose (requiring medical attention) with following group of medications:
    • benzodiazepines, antiepileptics, stimulants or attempt via hanging (asphyxiation) leading to anoxia.

For healthy participants

  • Any active or past psychiatric diagnoses screened by MINI/MINI-KID will be considered as exclusion criteria.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Paul Croarkin, D.O., M.S.

Closed for enrollment

Contact information:

Deniz Doruk Camsari M.D.



More information


Publications are currently not available

Mayo Clinic Footer